Burning Rock Biotech (BNR) AI Stock Analysis

• Market Cap: $86.58M
• Dividend Yield: N/A
• Average Volume (3M): 22.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: 5.33%
• EPS Growth: 75.52%
• Country: US
• Employees: 674
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.13
• Shares Outstanding: 9,034,111
• 10 Day Avg. Volume: 13,298
• 30 Day Avg. Volume: 22,645
• PEG Ratio: <0.01
• Price to Book (P/B): 0.09
• Price to Sales (P/S): 0.10
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: -0.28
• Enterprise Value/Revenue: -0.04
• Enterprise Value/Gross Profit: -0.06
• Enterprise Value/Ebitda: 0.24
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: $6.00 ▼(-31.03% Downside)

The overall score is impacted primarily by financial challenges, including declining revenue and negative cash flow, despite the positive technical momentum. Valuation remains a concern due to ongoing losses. The lack of additional data from earnings calls or corporate events means the score is weighted heavily toward financial performance and technical analysis.

Burning Rock Biotech Business Overview & Revenue Model

Company Description

Burning Rock Biotech (BNR) is a leading biotechnology company focused on the development of innovative cancer diagnostics. Operating primarily in the healthcare and biotechnology sectors, the company specializes in next-generation sequencing (NGS) solutions that enable precision oncology. Burning Rock Biotech provides a comprehensive suite of products and services, including diagnostic tests for early cancer detection, treatment selection, and monitoring of disease progression, aimed at improving patient outcomes.

How the Company Makes Money

Burning Rock Biotech generates revenue primarily through the sale of its proprietary next-generation sequencing-based diagnostic tests. These tests are used by healthcare providers and research institutions for early cancer detection, treatment selection, and monitoring. The company leverages its advanced technology platform to offer a range of tests that cater to different types of cancer. Additionally, Burning Rock Biotech collaborates with pharmaceutical companies and research organizations, forming strategic partnerships that contribute to its revenue stream by providing companion diagnostics and supporting drug development efforts. The company's earnings are influenced by the growing demand for precision medicine and advancements in cancer diagnostics.

Burning Rock Biotech Financial Statement Overview

Summary

Burning Rock Biotech faces significant financial challenges with declining revenues and persistent net losses. While the balance sheet is relatively stable with low leverage, negative cash flow from operations is a concern. The company needs to enhance revenue generation and operational efficiency to improve its financial health.

Income Statement

Burning Rock Biotech shows a declining revenue trend with a negative revenue growth rate of -4.03% from 2023 to 2024. Gross profit margin is relatively stable but the net profit margin remains deeply negative due to substantial net losses. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges and inefficiencies. The company needs to focus on revenue stabilization and cost control to improve its income statement.

Balance Sheet

The company's balance sheet shows a relatively healthy equity ratio with stockholders' equity forming a significant part of total assets. The debt-to-equity ratio is low at 0.09, indicating low leverage which is a positive sign for financial stability. However, the return on equity is negative due to consistent net losses, which impacts the overall attractiveness of the balance sheet.

Cash Flow

Burning Rock Biotech's cash flow statement reflects negative operating cash flows, though there is an improvement from the previous year. Free cash flow remains negative, reflecting ongoing cash burn. The operating cash flow to net income ratio is challenging due to both figures being negative, and the company needs to improve cash generation from operations to sustain long-term growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	536.30M	515.82M	537.43M	563.24M	507.86M	429.90M
Gross Profit	386.77M	362.40M	363.23M	380.04M	364.15M	313.92M
EBITDA	-99.22M	-270.23M	-517.90M	-856.31M	-746.50M	-373.26M
Net Income	-140.24M	-346.63M	-653.69M	-971.23M	-796.70M	-407.24M
Balance Sheet
Total Assets	824.93M	885.30M	1.04B	1.59B	2.28B	2.66B
Cash, Cash Equivalents and Short-Term Investments	452.72M	519.85M	615.10M	905.45M	1.50B	2.26B
Total Debt	39.13M	52.32M	12.32M	50.79M	86.69M	46.88M
Total Liabilities	260.70M	304.48M	271.59M	429.13M	433.28M	242.02M
Stockholders Equity	564.24M	580.83M	768.41M	1.16B	1.85B	2.42B
Cash Flow
Free Cash Flow	-84.51M	-98.24M	-265.17M	-518.84M	-691.33M	-153.08M
Operating Cash Flow	-79.09M	-92.26M	-255.78M	-456.81M	-477.89M	-73.54M
Investing Cash Flow	-3.12M	-4.41M	-9.30M	-7.46M	81.70M	-109.31M
Financing Cash Flow	1.93M	-72.00K	-48.83M	-86.24M	-52.90M	2.17B

Burning Rock Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNR, the sentiment is Positive. The current price of 8.7 is below the 20-day moving average (MA) of 8.77, above the 50-day MA of 8.60, and above the 200-day MA of 5.73, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 23.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNR.

Burning Rock Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNR	51 Neutral	$86.58M	―	-22.66%	―	5.33%	75.52%
SERA	46 Neutral	$128.27M	―	-44.24%	―	0.93%	13.99%
VNRX	43 Neutral	$53.34M	―	―	―	35.10%	39.15%
BDSX	42 Neutral	$52.96M	―	-219.68%	―	25.70%	39.25%
BNGO	41 Neutral	$18.54M	―	-118.26%	―	-25.02%	85.08%
TRIB	41 Neutral	$17.87M	―	―	―	-4.40%	-6.31%

Burning Rock Biotech Corporate Events

Burning Rock Biotech Reports Improved Q2 2025 Financial Results

Burning Rock Biotech reported its financial results for the second quarter of 2025, showing a 9.6% increase in total revenues compared to the same period in 2024. The company achieved a gross profit of RMB108.1 million, a 13.3% increase from the previous year, and significantly reduced its net loss to RMB9.7 million from RMB108.0 million in 2024. The results reflect a strategic shift towards in-hospital testing and increased pharma R&D services, alongside effective cost control measures that reduced operating expenses by 42.1%.